

BACILLUS CLAUSII

Clinically Studied Oral Suspension Portfolio

RESTORE.
BALANCE.
LIVE BETTER.

Small
Spores.
Big
Possibilities.

ENHANCEMENT OF INTENSTINAL ECOLOGY



SCAN TO VISIT
OUR WEBSITE



RESTORE | BALANCE | LIVE BETTER

TRUSTED PROBIOTIC CARE
FOR EVERYDAY WELLNESS

Endogermila®

Bacillus clausii Oral Suspension

2 Billion CFU / 5 mL

Shelf life: 24 Months

- Supports gut microbiome balance
- Clinically studied for diarrhoea and related symptoms



Endogermila® PLUS

High-Strength Bacillus clausii Oral Suspension

4 Billion CFU / 5 mL

Shelf life: 24 Months

- Double-strength probiotic support
- Advanced microbiome restoration





MORE THAN PROBIOTICS
A STRONGER TOMORROW

ADVANCED NUTRITIONAL SUPPORT
FOR GUT & IMMUNE HEALTH

Endogermila® Advanced

Bacillus clausii + FOS + Zinc

2 Billion CFU / 5 mL

Shelf life: 24 Months

- Prebiotic and zinc support
- Gut + immune health



Endogermila® Advanced PLUS

Bacillus clausii + FOS + Zinc

4 Billion CFU / 5 mL

Shelf life: 24 Months

- Higher probiotic strength
- Prebiotic and zinc support





SCIENCE
STRAINS
BETTER LIVES

Multi-Strain Microbiome Solutions

MULTIPLE STRAINS. A HEALTHIER TOMORROW.

Triogermila®

Multi-Strain Bacillus Oral Suspension

6 Billion CFU / 5 mL

Shelf life: 24 Months

- Broad-spectrum gut restoration
- Supports overall gut health



Triogermila® 10B

Double-Potency Multi-Strain Probiotic

10 Billion CFU / 5 mL

Shelf life: 24 Months

- Quad-strain advanced formula
- Post-antibiotic recovery support



CLINICAL PROOF → MARKET CONTEXT → COMMERCIAL VALUE

WHY OUR BACILLUS CLAUSII SOLUTION STANDS APART

BEYOND BILLIONS OF CFU

In a category where 2 Billion CFU / 5 mL is commonly available, stronger differentiation comes from the evidence behind the finished formulation.

CATEGORY COMPARISON

TYPICAL CATEGORY POSITIONING	ELMED VALUE PROPOSITION
CFU-led communication	Clinical-outcome-led communication
2B / 5 mL oral suspension positioning	2B / 5 mL evaluated as the finished formulation
General gut-flora / diarrhoea support	Quantified outcomes versus placebo
Symptom-focused probiotic story	Frequency, duration, stool consistency + biomarkers + QoL
General tolerability message	Safety and tolerability assessed in the study

CLINICAL DIFFERENTIATION IN NUMBERS

24.6%

Lower episode frequency
vs placebo

24.4%

Shorter mean duration
vs placebo

DAY 5

Stool normalization
all treated subjects

5 AREAS

Multi-outcome evidence
symptoms + biomarkers + QoL

VALUE BEYOND CFU COUNT

DEFINED FORMAT

Bacillus clausii spore suspension

CLINICAL EVIDENCE

Randomized, double-blind,
placebo-controlled

TARGETED OUTCOMES

Frequency . Duration . Stool
consistency . Biomarkers . QoL

B2B TRANSLATION

Scientific positioning + manufacturing
/ formulation support

WHAT THIS MEANS FOR OUR PARTNERS

- Evidence-based product positioning
- Clear differentiation beyond CFU count
- Clinical data for scientific communication
- Premium B2B product narrative
- Technical & formulation support from ELMED
- Private-label / customized opportunities

Category-level comparison reflects common market positioning; individual competing products may have different evidence, formulations and claims.

CLINICAL EVIDENCE -> KEY CLAIMS

CLINICALLY SUPPORTED PERFORMANCE

Randomized, double-blind, placebo-controlled clinical evaluation in adults with acute diarrhoea.

N = 70
35 per arm

7 DAYS
once-daily dosing

2 BILLION CFU
per 5 mL

24.6% LOWER EPISODE FREQUENCY

Mean episodes: 9.03 vs 11.97 with placebo. $p = 0.0007$

24.4% SHORTER MEAN DURATION

Mean duration: 2.42 vs 3.20 days with placebo. $p = 0.0003$

DAY 5 STOOL NORMALIZATION

All subjects in the B. clausii group recorded Bristol Stool Form scores 3-4 by Day 5.

BEYOND SYMPTOM CONTROL

INFLAMMATORY BIOMARKERS

Greater improvements versus placebo were observed for fecal calprotectin, CRP and ESR.

QUALITY OF LIFE

SF-12 total, physical and mental component scores improved significantly by study end versus placebo.

SAFETY & TOLERABILITY

No serious adverse events were reported; study AEs were mild and assessed as unrelated to the investigational product

CLINICALLY DEMONSTRATED BENEFITS

- **Reduced diarrhoeal burden**

Fewer diarrhoeal episodes versus placebo during the study period.

- **Faster stool normalization**

Progressive improvement in Bristol Stool Form scores from Day 2 onward.

- **Shorter episode duration**

Significant reduction in mean diarrhoeal duration versus placebo

- **Broader clinical benefit**

Significant improvements in selected inflammatory biomarkers and health-related quality-of-life measures.

Claims derived from Study LCBS-ELS-177. Clinical communication should be adapted to applicable local regulatory requirements.

ELMED Life Sciences Pvt. Ltd.

 www.elmedlifesciences.com

 info@elmedlifesciences.com

 040-29568336

 104, First Floor, 36 Pinnacle,
Road No. 36, Jubilee Hills Check Post Road,
Hyderabad, Telangana 500033, India



**Explore Our
Microbiome Solutions**